MedPath

Efficacy of Duloxetine Compared to NSIADs in Osteoarthritis of Knee

Phase 2
Completed
Conditions
Osteo Arthritis Knee
Interventions
Drug: Nonsteroidal Antiinflammatory Drug
Registration Number
NCT05486026
Lead Sponsor
Hawler Medical University
Brief Summary

Osteoarthritis (OA) is the most common degenerative joint disease, affecting more than 25% of the population . Knee OA is an insidious disease related to structural changes in the joint over many years. Progressive articular damage results in a loss of the extracellular matrix of cartilage in addition to changes in subchondral bone.

Duloxetine, a selective serotonin, and norepinephrine reuptake inhibitor, it seems to be effective in treating neuropathic and chronic pain conditions.

Detailed Description

This will be a 13-week A randomized open labelled clinical trail in Iraqi Kurdistan Region, that will be designed to assess the efficacy of duloxetine tablet compared with other group (Nonsteroidal anti-inflammatory) drug on the reduction of pain caused by osteoarthritis of the knee.

Patients will be divided into two groups, first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. Patients will be observed at visits (0) baseline then at second visits at 13 weeks then will be compared to control group that will receive NSAID (nonsteroidal anti-inflammatory drug) at baseline (0) visit then 2nd visits at 13 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria
  1. > 40years of age
  2. both Genders
  3. who will meet the American College of Rheumatology clinical and radiographic criteria for the diagnosis of osteoarthritis of the knee
  4. with pain for ≥14days of each separate month for 3months before study entry, with a mean score ≥4 on the 24-h average pain score (0-10) using the average of daily ratings
Exclusion Criteria
  1. if they have diagnosed with inflammatory arthritis or an autoimmune disease
  2. if they received invasive therapy in last 3 months (knee arthroscopy) or knee replacement at any time
  3. patients with psychiatric disorders
  4. Hypertension
  5. Heart disease
  6. patients on antipsychotics or anti-depressant -

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Duloxetine tabletNonsteroidal Antiinflammatory DrugPatient in the first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals for 13 weeks .
NSAID(non steroidal anti inflammatory)Duloxetine 30 MGpatient in the second group will receive NSAID(non-steroidal anti inflammatory) drugs for 13 weeks
Duloxetine tabletDuloxetine 30 MGPatient in the first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals for 13 weeks .
NSAID(non steroidal anti inflammatory)Nonsteroidal Antiinflammatory Drugpatient in the second group will receive NSAID(non-steroidal anti inflammatory) drugs for 13 weeks
Primary Outcome Measures
NameTimeMethod
twenty four hour 24-h average pain scores (short form) in patients with osteoarthritis knee painfollow-up patients within two months

it will report in patients' diaries based on the 11-point Likert scale (an ordinal scale with 0 indicating 'no pain', and 10 indicating 'worst pain imaginable')

(WOMAC) WESTERN ONTARIO AND MCMASTER OSTEOARTHITIS INDEX used for evaluation of pain in knee Osteoarthritisfollow-up patients within two months

which involve three category about rating of pain(5 item) , stiffness(2item), physical function(17 item

Secondary Outcome Measures
NameTimeMethod
The other modality (clinical global improvement)follow-up patients within two months

will be used for severity of modality of pain and therapeutic response even side effect of drug

Trial Locations

Locations (1)

Rizgary and Cmc Hospital

🇮🇶

Erbil, Iraq

© Copyright 2025. All Rights Reserved by MedPath